Rheumatoid Arthritis | Chart Trends | US | 2014
The Rheumatoid Arthritis (RA) treatment paradigm continues to evolve as new therapeutic options are added to physicians’ toolkits. The positioning of newer agents (e.g., Pfizer’s Xeljanz, Janssen’s Simponi Aria) in the treatment algorithm is still being established in some cases, and has reached a relative steady state in others. ChartTrends®: Rheumatoid Arthritis (US) 2014 explores the current status quo in RA treatment based on both physician reports and actual practice through the use of patient chart data.
Related Market Assessment Reports
Report
Chronic Kidney Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Kidney Disease (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises therapies, which are…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious renal and CNS manifestations…
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
